Otsuka Pharmaceutical
Otsuka Pharmaceutical Co., Ltd., commonly referred to as Otsuka, is a leading global healthcare company headquartered in Japan. Established in 1964, Otsuka has made significant strides in the pharmaceutical and nutraceutical industries, focusing on innovative solutions for mental health, oncology, and general healthcare. With a strong presence in regions such as North America, Europe, and Asia, Otsuka is renowned for its unique products, including the antipsychotic medication Abilify and the hydration solution Pocari Sweat. The company’s commitment to research and development has positioned it as a pioneer in addressing unmet medical needs. Otsuka's dedication to innovation and patient care has earned it a notable reputation in the global market, making it a key player in the pharmaceutical landscape.
DitchCarbon Score
How does Otsuka Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Otsuka Pharmaceutical's score of 25 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Otsuka Pharmaceutical's reported carbon emissions
In 2023, Otsuka Pharmaceutical reported total carbon emissions of approximately 523,000,000 kg CO2e globally, comprising 327,309,000 kg CO2e from Scope 1, 195,362,000 kg CO2e from Scope 2, and 664,646,000 kg CO2e from Scope 3 emissions. In Japan, the company recorded Scope 1 emissions of about 123,190,000 kg CO2e and Scope 2 emissions of approximately 30,537,000 kg CO2e. Otsuka has set a long-term commitment to achieve "Net Zero" emissions by 2050, aiming to reduce the total environmental impact of its business activities to zero. This initiative is part of their 2050 Environmental Vision, which includes establishing an integrated energy service structure under a retail electricity provider model, starting in 2023. In 2022, Otsuka's global Scope 1 and 2 emissions were reported at approximately 576,000,000 kg CO2e, indicating a reduction from previous years. The company continues to focus on sustainability and reducing its carbon footprint across all scopes of emissions, reflecting its commitment to environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Get Started| 2011 | 2012 | 2017 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 285,728,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 116,816,000 | 000,000,000 | - | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 402,544,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Otsuka Pharmaceutical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
